Berkeley Springs, WV—Potomac Airpark, VOR RWY 29, Amdt. 4
Prairie Du Chien, WI—Prairie Du Chien Muni, VOR/DME RWY 29, Amdt. 5

. . . effective 16 April 1986

Raleigh-Durham, NC—Raleigh Durham, RADAR-1, Amdt. 4

. . . effective 9 April 1986

Afton, OK—Shangri-La, RNAV RWY 17, Amdt. 1
Afton, OK—Shangri-La, RNAV RWY 35, Amdt. 1
Grove, OK—Grove Muni, RNAV RWY 18, Amdt. 2
Grove, OK—Grove Muni, RNAV RWY 36, Amdt. 2
Bluefield, WV—Mercer County, ILS RWY 23, Amdt. 9

. . . effective 8 April 1986

Raleigh-Durham, NC—Raleigh-Durham, ILS RWY 23R, Amdt. 1

The FAA published an Amendment in Docket No. 24960, Amdt. No. 1318, to Part 97 of the Federal Aviation Regulations (VOL 51 FR No. 70 Page 12515; dated 11 APR 86) under § 97.35, effective 8 MAY 1986, which is hereby amended as follows:

ASTORIA, OR—PORT OF ASTORIA, COPTER ILS/DME 255–B, ORIG., IS RESCINDED.

[FR Doc. 86–9251 Filed 4–24–86; 8:45 am]

BILLING CODE 4910–13–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 522

Implantation or Injectable Dosage From New Animal Drugs Not Subject to Certification; Gentamicin Sulfate Injection

AGENCY: Food and Drug Administration HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Med-Tech, Inc., providing for use of gentamicin sulfate injection in the treatment of urinary tract infections (cystitis) in dogs.

EFFECTIVE DATE: April 25, 1986.

FOR FURTHER INFORMATION CONTACT: Bob G. Griffith, Center for Veterinary Medicine (HFV–110), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–1963.

SUPPLEMENTARY INFORMATION: Med-Tech, Inc., P.O. Box 338, Elwood, KS 66024, filed NADA 137–310 for gentamicin sulfate injection (50 milligrams per milliliter). The drug is for intramuscular or subcutaneous injection in dogs for the treatment of urinary tract infections (cystitis) caused by *Proteus mirabilis, Escherichia coli,* and *Staphylococcus aureus.* The NADA is approved and the regulations amended to reflect the approval. The basis for approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of Part 20 (21 CFR Part 20) and § 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Lane, Rockville, MD 20857, from 9 a.m. to 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.24(d)(1)(i) (April 26, 1985; 50 FR 16636) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

List of Subjects in 21 CFR Part 522

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, Part 522 is amended as follows:

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FROM NEW ANIMAL DRUGS NOT SUBJECT TO CERTIFICATION

1. The authority citation for 21 CFR Part 522 continues to read as follows:

Authority: Sec. 512(i), 82 Stat. 347 (21 U.S.C. 360b(i)); 21 CFR 5.10 and 5.83.

2. Section 522.1044 is amended by adding new paragraphs (b)(3) and (d)(5) to read as follows:

§ 522.1044 Gentamicin sulfate injection.

* * * * *

(b) * * *

(3) See No. 013983 for use of 50 milligram-per-milliliter solution in dogs as in paragraph (d)(5) of this section.

* * * * *

(d) * * *

(5) *Dogs.*—(i) *Amount.* 2 milligrams of gentamicin per pound of body weight, twice daily on the first day, then once daily.

(ii) *Indications for use.* For use in the treatment of urinary tract infections (cystitis) caused by *Proteus mirabilis, Escherichia coli,* and *Staphylococcus aureus.*

(iii) *Limitations.* Administer intramuscularly or subcutaneously. If no improvement is seen after 3 days, treatment should be discontinued and the diagnosis reevaluated. Treatment not to exceed 7 days. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dated: April 21, 1986.

Gerald B. Guest,

Acting Director, Center for Veterinary Medicine.

[FR Doc. 86–9267 Filed 4–24–86; 8:45 am]

BILLING CODE 4160–01–M

21 CFR Parts 601, 610, 620, 630, 640, 650, 660, and 680

[Docket No. 86N–0113]

Biological Products; Corrections and Technical Amendments

AGENCY: Food and Drug Administration.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending its regulations on biological products to correct editorial and typographical errors and to make minor, noncontroversial, technical revisions.

DATES: Effective April 25, 1986; written comments by May 27, 1986.

ADDRESS: Written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Joseph G. Wilczek, Center for Drugs and Biologics (HFN–362), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–295–8049.

SUPPLEMENTARY INFORMATION: FDA is amending certain of its biological products regulations to correct editorial and typographical errors. FDA is also making certain revisions in § 610.53 in the table of dating periods for licensed biological products. These changes represent current practice with respect to the storage periods for various products. FDA has accepted these periods in submitted license applications.

Because this final rule is not controversial and because when effective it provides notice of accepted standards, notice and comment procedure and delayed effective date are found to be unnecessary and not in the public interest (5 U.S.C. 553 (b)(B) and (d)). This final rule, therefore, is

effective April 25, 1986. However, interested persons may, on or before May 27, 1986, submit written comments to the Dockets Management Branch (address above).

FDA has analyzed the regulatory impact of this rule in accordance with Executive Order 12291 and the Regulatory Flexibility Act (Pub. L. 96-354). The rule amends the regulations on biological products to correct editorial and typographical errors and to make minor technical revisions. Therefore, the agency has determined that the rule is not a major rule as defined in Executive Order 12291. Further, FDA certifies that the rule will not have a significant impact on a substantial number of small entities, as defined by the Regulatory Flexibility Act.

The agency has determined under 21 CFR 25.24(a)(9) (April 26, 1985; 50 FR 16636) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

List of Subjects

21 CFR Part 601

Biologics.

21 CFR Part 610

Biologics; Labeling; Reporting and recordkeeping requirements.

21 CFR Part 620

Biologics; Reporting and recordkeeping requirements.

21 CFR Part 630

Biologics.

21 CFR Part 640

Blood; Labeling; Reporting and recordkeeping requirements.

21 CFR Part 650

Biologics.

21 CFR Part 660

Biologics; Labeling.

21 CFR Part 680

Biologics; Blood.

Therefore, under the Public Health Service Act and under the authority delegated to the Commissioner of Food and Drugs, Parts 601, 610, 620, 630, 640, 650, 660, and 680 are amended as follows:

PART 601—LICENSING

1. The authority citation for 21 CFR Part 601 is revised to read as follows:

Authority: Secs. 215, 351, 58 Stat. 690 as amended, 702 as amended (42 U.S.C. 216, 262); 21 CFR 5.10.

§ 601.25 [Amended]

2. Section 601.25 *Review procedures to determine that licensed biological products are safe, effective, and not misbranded under prescribed, recommended, or suggested conditions of use* is amended in paragraph (d)(2) by changing "§ 314.111(a)(5)(ii)" to read "§ 314.126."

PART 610—GENERAL BIOLOGICAL PRODUCT STANDARDS

3. The authority citation for 21 CFR Part 610 is revised to read as follows:

Authority: Sec. 351, 58 Stat. 702 as amended (42 U.S.C. 262); 21 CFR 5.10.

§ 610.9 [Amended]

4. In § 610.9 *Equivalent methods and processes,* in paragraph (b) changing "20205" to read "20892."

§ 610.11 [Amended]

5. In § 610.11 *General safety,* in the introductory paragraph, in the introductory text of paragraph (c), (c)(2), and (3) by changing the reference "paragraph (f) of this section" to read "§ 610.9" wherever it appears.

§ 610.15 [Amended]

6. In § 610.15 *Constituent materials,* in the introductory text of praragraph (a) by revising in the second sentence the word "use" to read "used," and in the third sentence by changing "in 50 percent or more glycerin" to read "in 50 percent or more volume in volume (v/v) glycerin."

§ 610.40 [Amended]

7. In § 610.40 *Test for hepatitis B surface antigen,* paragraphs (b)(4), (d)(1)(v), and (d)(2)(iv), by changing "20205" to read "20892."

8. Section 610.53 is amended in paragraph (c) by revising the table to read as follows:

§ 610.53 Dating periods for licensed biological products.

* * * * *

(c) * * *

Product	Manufacturer's storage period 1 to 5 °C (unless otherwise stated)	Manufacturer's storage period 0 °C or colder (unless otherwise stated)	Dating period after leaving manufacturer's storage when stored at 2 to 8 °C (unless otherwise stated)
A	B	C	D
Adenovirus Vaccine Live Oral	6 months	Not applicable	6 months.
Albumin (Human)	3 years	do	(a) 5 years.
	do	do	(b) 3 years, provided labeling recommends storage at room temperature, no warmer than 37 °C.
	Not applicable	do	(c) 10 years, if in a hermetically sealed metal container and provided labeling recommends storage between 2 and 8 °C.
Allergenic Extracts labeled "No U.S. Standard of Potency":			
1. With 50 percent or more glycerin	3 years	do	3 years.
2. With less than 50 percent glycerin	18 months	do	18 months.
3. Products for which cold storage conditions are inappropriate	Not applicable	do	18 months (from date of manufacture), provided labeling recommends storage at 30 °C or colder.
4. Powders and tablets	do	do	5 years (from date of manufacture), provided labeling recommends storage at 30 °C or colder.
5. Preeze-dried products:			
a. Unreconstituted	do	do	4 years (from date of manufacture).
b. Reconstituted	do	do	18 months (cannot exceed 4-year unreconstituted dating period plus an additional 12 months).
Allergenic Extracts, Alum Precipitated labeled "No U.S. Standard of Potency".	18 months	do	18 months.
Anthrax Vaccine Adsorbed	2 years	do	1 year.
Antibody to Hepatitis B Surface Antigen:			
1. Antibody to Hepatitis B Surface Antigen	6 months	do	6 months.
2. Lyophilized coated red blood cells	do	do	Do.
3. Enzyme conjugated products	do	do	Do.
Iodinated (^{125}I) products	Not applicable	do	45 days (from date of manufacture).
Antihemophilic Factor (Human)	do	do	1 year (from date of manufacture).

Product	Manufacturer's storage period 1 to 5 °C (unless otherwise stated)	Manufacturer's storage period 0 °C or colder (unless otherwise stated)	Dating period after leaving manufacturer's storage when stored at 2 to 8 °C (unless otherwise stated)
A	B	C	D
Anti-Human Globulin Liquid	do	do	2 years.
Anti-Inhibitor Coagulant Complex	do	do	Do.
Antirabies Serum	1 year	do	Do.
Antivenin (*Crotalidae*) Polyvalent	do	do	5 years with an initial 10 percent excess of potency, provided labeling recommends storage at 37 °C or colder.
Antivenin (*Latrodectus Mactans*)	do	do	5 years with an initial 10 percent excess of potency.
Antivenin (*Micurus fulvius*)	do	do	Do.
Asparaginase	Not applicable	do	18 months from the date of the last valid potency test.
BCG Vaccine	1 year	Not applicable	6 months.
Blood Grouping Serums			
1. Liquid	Not applicable	Not applicable	2 years.
2. Dried	1 year	2 years	5 years.
Blood Group Substance AB	do	do	2 years.
Blood Group Substance A	do	do	Do.
Blood Group Substance B	do	do	Do.
Botulism Antitoxin	do	Not applicable	5 years with an initial 20 percent excess of potency.
Cholera Vaccine	do	do	18 months.
Coccidioidin	do	do	3 years.
Collagenase	Not applicable	do	4 years (from date of manufacture), provided labeling recommends storage at 37 °C or colder.
Cryoprecipitated AFH	do	do	12 months from the date of collection of source blood, provided labeling recommends storage at −18 °C or colder.
Diphtheria Antitoxin:			
1. Liquid	1 year	do	5 years with an initial 20 percent excess of potency.
2. Dried	do	2 years	5 years with an initial 10 percent excess of potency.
Diphtheria and Tetanus Toxoids and Pertussis Vaccine Adsorbed	do	Not applicable	18 months.
Diphtheria and Tetanus Toxoids, Adsorbed	do	do	2 years.
Diphtheria Toxin for Schick Test	do	do	1 year.
Diphtheria Toxoid	do	do	2 years.
Diphtheria Toxoid Adsorbed	do	2 years	Do.
Diphtheria Toxoid-Schick Test Control	Not applicable	Not applicable	1 year.
Factor IX Complex	do	do	1 year (from date of manufacture).
Fibrinolysin (Human)	1 year	2 years	2 years.
Fibrinolysin and Desoxyribonuclease Combined (Bovine)	do	do	3 years, provided labeling recommends storage at 30 °C or colder.
Fibrinolysin and Desoxyribonuclease Combined (Bovine) with Chloramphenicol.	do	do	Do.
Hepatitis B Surface Antigen:			
1. Unlyophilized coated red blood cells	Not applicable	do	14 days (from date of manufacture).
2. Iodinated (^{125}I) product	do	do	45 days (from date of manufacture).
3. Enzyme conjugated product	6 months	do	6 months.
Histoplasmin	1 year	Not applicable	2 years.
Immunoglobulins:			
1. Hepatitis B Immune Globulin (Human)	Not applicable	2 year	1 year.
2. Immune Globulin (Human)	3 years	do	3 years.
3. Immune Globulin Intravenous (Human)	Not applicable	do	1 year.
4. Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine)	do	Not applicable	2 years.
5. Pertussis Immune Globulin (Human)	3 years	do	3 years from date the dried or frozen bulk product is placed in final solution.
6. Rabies Immune Globulin (Human)	1 years	do	1 year.
7. Rh_o(D) Immune Globulin (Human)	6 months	do	6 months.
8. Tetanus Immune Globulin (Human)	1 year	do	3 years with an initial 10 percent excess of potency.
9. Vaccinia Immune Globulin (Human)	3 years	do	3 years.
10. Varicella-Zoster Immune Globulin (Human)	Not applicable	do	1 year.
Hepatitis B Vaccine	2 years at 12 to 8 °C	Not applicable	3 years.
Influenza Virus Vaccine	1 year	do	18 months.
Limulus Amebocyte Lysate	Not applicable	Not applicable	18 months (from date of manufacture).
Measles, Mumps, and Rubella Virus Vaccine Live	do	1 year (−20 °C or colder).	1 year.
Measles and Mumps Virus Vaccine Live	do	do	1 year.
Measles and Rubella Virus Vaccine Live	do	do	Do.
Measles Live and Smallpox Vaccine	Not applicable	do	1 year (from date of manufacture).
Measles Virus Vaccine Live	do	do	1 year.
Meningococcal Polysaccharide Vaccine Group A:			
1. Final bulk powder	do	2 years (−20 °C or colder).	Not applicable.
2. Final container	Not applicable	3 years (−20 °C or colder).	2 years.
Meningococcal Polysaccharide Vaccine Group C:			
1. Final bulk powder	do	2 years (−20 °C or colder).	Not applicable.
2. Final container	do	3 years (−20 °C or colder).	2 years.
Meningococcal Polysaccharide Vaccine Groups A and C combined:			
1. Final bulk powder	do	2 years (−20 °C or colder).	Not applicable.
2. Final container	do	3 years (−20 °C or colder).	2 years.
Meningococcal Polysaccharide Vaccine Groups A, C, Y, and W135 combined:			
1. Final bulk power	do	2 years (−20 °C or colder).	Not applicable.
2. Final container	do	3 years (−20 °C or colder).	2 years.
Mumps Skin Test Antigen	6 months	Not applicable	18 months.
Mumps Virus Vaccine Live	Not applicable	1 year (−20 °C or colder).	1 year.
Normal Horse Serum	1 year	2 years	5 years.
Pertussis Vaccine	do	Not applicable	18 months.

Product A	Manufacturer's storage period 1 to 5 °C (unless otherwise stated) B	Manufacturer's storage period 0 °C or colder (unless otherwise stated) C	Dating period after leaving manufacturer's storage when stored at 2 to 8 °C (unless otherwise stated) D
Pertussis Vaccine Adsorbed	do	do	Do.
Plague Vaccine	do	do	Do.
Plasma products:			
1. Fresh Frozen Plasma	Not applicable	do	1 year from date of collection of source blood (−18 °C or colder).
2. Liquid Plasma	do	do	(a) 26 days from date of collection of source blood (between 1 and 6 °C). (b) 40 days from date of collection of source blood only when CPDA-1 solution is used as the anticoagulant (between 1 and 6 °C).
3. Plasma	do	do	5 years from date of collection of source blood (−18 °C or colder).
4. Platelet Rich Plasma	do	do	72 hours from time of collection of source blood, provided labeling recommends storage (20 to 24 °C or between 1 and 6 °C). 5 days if certain approved containers are used (20 to 24 °C).
5. Source Leukocytes	do	do	In lieu of expiration date, the collection date shall appear on the label.
6. Source Plasma	do	do	10 years (at the recommended storage temperature stated on the label).
7. Therapeutic Exchange Plasma	do	do	10 years.
Plasma Protein Fraction (Human)	1 year	do	(a) 5 years. (b) 3 years provided labeling recommends storage at room temperature, no warmer than 30 °C).
Platelets	Not applicable	do	72 hours from time of collection of source blood, provided labeling recommends storage at 20 to 24 °C or between 1 and 6 °C. 5 days if certain approved containers are used (20 to 24 °C).
Pneumococcal Vaccine Polyvalent:			
1. Final bulk powder	do	24 months after potency assay (−20 °C or colder).	Not applicable.
2. Final container	do	Not applicable	2 years (from date of manufacture).
Poliovirus Vaccine Inactivated	1 year	do	1 year.
Poliovirus Vaccine Live Oral Trivalent:			
1. Frozen	Not applicable	1 year (−10 °C or colder).	1 year, provided labeling recommends storage at a temperature which will maintain ice continuously in a solid state.
2. Liquid	do	Not applicable	30 days, provided labeling recommends storage between 2 and 8 °C and container has been unopened.
Poliovirus Vaccine Live Oral Type I:			
1. Frozen	do	1 year (−10 °C or colder).	1 year, provided labeling recommends storage at a temperature which will maintain ice continuously in a solid state.
2. Liquid	do	Not applicable	30 days, provided labeling recommends storage between 2 and 8 °C and container has been unopened.
Poliovirus Vaccine Live Oral Type II:			
1. Frozen	do	1 year (−10 °C or colder).	1 year, provided labeling recommends storage at a temperature which will maintain ice continuously in a solid state.
2. Liquid	do	Not applicable	30 days, provided labeling recommends storage between 2 and 8 °C and container has been unopened.
Poliovirus Vaccine Live Oral Type III:			
1. Frozen	do	1 year (−10 °C or colder).	1 year, provided labeling recommends storage at a temperature which will maintain ice continuously in a solid state.
2. Liquid	do	Not applicable	30 days, provided labeling recommends storage between 2 and 8 °C and container has been unopened.
Polyvalent bacterial antigens with "No U.S. Standard of Potency" liquid.	1 year	do	18 months.
Polyvalent bacterial vaccines with "No U.S. Standard of Potency" liquid.	do	do	Do.
Rabies Vaccine:			
1. Dried	do	2 years	Do.
2. Liquid	3 months	Not applicable	6 months.
Reagent Red Blood Cells	Not applicable	do	35 days from earliest date of collection.
ACD Red Blood Cells	do	do	(a) 21 days from date of collection of source blood, provided labeling recommends storage between 1 and 6 °C and the hermetic seal is not broken during processing. (b) 24 hours after plasma removal, provided labeling recommends storage between 1 and 6 °C and the hermetic seal is broken during processing.
CPD Red Blood Cells	do	do	(a) 21 days from date of collection of source blood, provided labeling recommends storage between 1 and 6 °C and the hermetic seal is not broken during processing. (b) 24 hours after plasma removal, provided labeling recommends storage between 1 and 6 °C and the hermetic seal is broken during processing.
CPDA-1 Red Blood Cells	do	do	(a) 35 days from date of collection of source blood, provided labeling recommends storage between 1 and 6 °C and the hermetic seal is not broken during processing. (b) 24 hours after plasma removal, provided labeling recommends storage between 1 and 6 °C and the hermetic seal is broken during processing.
Red Blood Cells Deglycerolized	do	do	24 hours after removal from storage at −65 °C or colder, provided labeling recommends storage between 1 and 6 °C.
Red Blood Cells Frozen	do	do	3 years from date of collection of source blood, provided labeling recommends storage at −65 °C or colder.
Rubella and Mumps Virus Vaccine Live	do	1 year (−20 °C or colder).	1 year.
Rubella Virus Vaccine Live	do	°C.	Do.
Skin Test Antigens for Cellular Hypersensitivity	6 months	Not applicable	Do.

—Continued

Product	Manufacturer's storage period 1 to 5 °C (unless otherwise stated)	Manufacturer's storage period 0 °C or colder (unless otherwise stated)	Dating period after leaving manufacturer's storage when stored at 2 to 8 °C (unless otherwise stated)
A	B	C	D
Smallpox Vaccine:			
1. Liquid	Not applicable	9 months (−10 °C or colder, if product is maintained as glycerinated or equivalent vaccine in bulk or final containers).	3 months, provided labeling recommends storage at 0 °C or colder.
3. Dried	6 months	Not applicable	18 months.
Streptokinase	Not applicable	do	Do.
Tetanus and Diphtheria Toxoids Adsorbed for Adult Use	1 year	do	2 years.
Tetanus Antitoxin:			
1. Liquid	do	do	5 years with an initial 20 percent excess or potency.
2. Dried	do	2 years	5 years with an initial 10 percent excess or potency.
Tetanus Toxoid	do	Not applicable	2 years.
Tetanus Toxoid Adsorbed	do	do	Do.
Thrombin	do	2 year	3 years.
Thrombin Impregnated Pad	Not applicable	Not applicable	1 year, or 6 months at 20 to 24 °C.
Tuberculin:			
1. Purified Protein Derivative, diluted	6 months	do	1 year.
2. Old or Purified Protein Derivative dried on multiple puncture device.	1 year (not to exceed 30 °C; do not refrigerate).	do	2 years, provided labeling recommends storage at a temperature not to exceed 30 °C. Do not refrigerate.
3. Old on multiple puncture device	do	do	Do.
Typhoid Vaccine	1 year	do	18 months.
ACD Whole Blood	Not applicable	do	21 days from date of collection, provided labeling recommends storage between 1 and 6 °C.
CPD Whole Blood	do	do	Do.
CPDA-1 Whole Blood	do	do	35 days from date of collection, provided labeling recommends storage between 1 and 6 °C.
Heparin Whole Blood	do	do	48 hours from date of collection, provided labeling recommends storage between 1 and 6 °C.
Yellow Fever Vaccine	do	1 year (−20 °C or colder).	1 year, provided labeling recommends storage at 5 °C or colder.

PART 620—ADDITIONAL STANDARDS FOR BACTERIAL PRODUCTS

9. The authority citation for 21 CFR Part 620 is revised to read as follows:

Authority: Secs. 215, 351, 58 Stat. 690 as amended, 702 as amended (42 U.S.C. 216, 262); 21 CFR 5.10.

§ 620.6 [Amended]

10. In § 620.6 *General requirements,* in paragraph (h) by changing "Building 29A, 9000 Rockville Pike, Bethesda, MD 20205" to read "8800 Rockville Pike, Bethesda, MD 20892."

§ 620.12 [Amended]

11. In § 620.12 *U.S. Standard preparations,* in the introductory paragraph by removing the word "National" and by changing "20205" to read "20892."

§ 620.14 [Amended]

12. In § 620.14 *General requirements,* in the introductory text of paragraph (c) by removing the word "National" and by changing "20205" to read "20892."

§ 620.24 [Amended]

13. In § 620.24 *General requirements,* in the introductory text of paragraph (c) by changing "Building 29A, 9000 Rockville Pike, Bethesda, MD 20205" to read "8800 Rockville Pike, Bethesda, MD 20892."

§ 620.35 [Amended]

14. In § 620.35 *General requirements,* in the introductory text of paragraph (e) by changing "20205" to read "20892."

§ 620.43 [Amended]

15. In § 620.43 *Reference BCG Vaccine,* by changing "20205" to read "20892."

§ 620.48 [Amended]

16. In § 620.48 *Samples; protocols; official release,* in the introductory text of paragraph (a) and in (a)(2) by changing "20205" to read "20892."

PART 630—ADDITIONAL STANDARDS FOR VIRAL VACCINES

17. The authority citation for 21 CFR Part 630 is revised to read as follows:

Authority: Secs. 215, 351, 58 Stat. 690 as amended, 702 as amended (42 U.S.C. 216, 262); 21 CFR 5.10.

§ 630.5 [Amended]

18. In § 630.5 *General requirements,* in the introductory text of paragraph (c) by changing "20205" to read "20892."

§ 630.16 [Amended]

19. In § 630.16 *Test for safety,* in paragraph (a)(6) by revising in the first sentence the phrase "At least 500 doses of 50 ml." to read "At least 500 doses or 50 mL."

§ 630.17 [Amended]

20. In § 630.17 *General requirements,* in the introductory text of paragraph (e) by changing "Building 29A, 9000 Rockville Pike, Bethesda, MD 20205" to read "8800 Rockville Pike, Bethesda MD 20892."

§ 630.36 [Amended]

21. In § 630.36 *General requirements,* in the introductory text of paragraph (h) by removing the phrase "Bldg. 29A" and by changing "20205" to read "20892."

§ 630.56 [Amended]

22. In § 630.56 *General requirements,* in the introductory text of paragraph (f) by changing "Building 29A, 9000 Rockville Pike, Bethesda, MD 20205" to read "8800 Rockville Pike, Bethesda, MD 20892."

§ 630.66 [Amended]

23. In § 630.66 *General requirements,* in the introductory text of paragraph (e) by removing the phrase "Bldg. 29A" and by changing "20205" to read "20892."

§ 630.75 [Amended]

24. In § 630.75 *General requirements,* in the introductory text of paragraph (d) by changing "Building 29A, 9000 Rockville Pike, Bethesda, MD 20205" to read "8800 Rockville Pike, Bethesda, MD 20892."

§ 630.86 [Amended]

25. In § 630.86 *General requirements,* in the introductory text of paragraph (e) by removing the phrase "Bldg. 29A" and by changing "20205" to read "20892."

PART 640—ADDITIONAL STANDARDS FOR HUMAN BLOOD AND BLOOD PRODUCTS

26. The authority citation for 21 CFR Part 640 continues to read as follows:

Authority: Secs. 215, 351, 58 Stat. 690 as amended; 702 as amended (42 U.S.C. 216, 262); 21 CFR 5.10.

§ 640.3 [Amended]

27. In § 640.3 *Suitability of donor,* in the introductory text of paragraphs (b) and (c), and paragraphs (d) and (e) by changing "Whole Blood (Human)" to read "Whole Blood."

§ 640.101 [Amended]

28. In § 640.101 *General requirements,* in the introductory text of paragraph (f) by changing "Building 29A, 9000 Rockville Pike, Bethesda, MD 20205" to read "8800 Rockville Pike, Bethesda, MD 20892."

§ 640.111 [Amended]

29. In § 640.111 *General requirements,* in the introductory text of paragraph (g) by changing "Building 29A, 9000 Rockville Pike, Bethesda, MD 20205" to read "8800 Rockville Pike, Bethesda, MD 20892."

PART 650—ADDITIONAL STANDARDS FOR DIAGNOSTIC SUBSTANCES FOR DERMAL TESTS

30. The authority citation for 21 CFR Part 650 is revised to read as follows:

Authority: Secs. 215, 351, 58 Stat. 690 as amended; 702 as amended (42 U.S.C. 216, 262); 21 CFR 5.10.

§ 650.11 [Amended]

31. In § 650.11 *General requirements,* in the introductory text of paragraph (c) by changing "Building 29A, 9000 Rockville Pike, Bethesda, MD 20205" to read "8800 Rockville Pike, Bethesda, MD 20892."

PART 660—ADDITIONAL STANDARDS FOR DIAGNOSTIC SUBSTANCES FOR LABORATORY TESTS

32. The authority citation for 21 CFR Part 660 is revised to read as follows:

Authority: Secs. 215, 351, 58 Stat. 690 as amended, 702 as amended (42 U.S.C. 216, 262); 21 CFR 5.10.

§ 660.6 [Amended]

33. In § 660.6 *Samples; protocols; official release,* in paragraph (a)(2) by changing "20205" to read "20892."

§ 660.22 [Amended]

34. In § 660.22 *Reference preparations* by changing "20205" to read "20892."

§ 660.29 [Amended]

35. In § 660.29 *Samples; protocols; official release,* in the introductory text of paragraph (a) by changing "20205" to read "20892."

§ 660.36 [Amended]

36. In § 660.36 *Samples and protocols,* in the introductory text of paragraph (a) by changing "20205" to read "20892."

§ 660.42 [Amended]

37. In § 660.42 *Reference panel* by changing "20205" to read "20892."

§ 660.46 [Amended]

38. In § 660.46 *Samples; protocols; official release,* in paragraph (a)(2) by changing "20205" to read "20892."

§ 660.52 [Amended]

39. In § 660.52 *Reference preparations* by changing "20205" to read "20892."

§ 660.53 [Amended]

40. In § 660.53 *Controls for serological procedures* by changing "20205" to read "20892."

§ 660.54 [Amended]

41. In § 660.54 *Potency tests, specificity tests, tests for heterospecific antibodies, and additional tests for nonspecific properties,* in the introductory paragraph by changing "20205" to read "20892."

§ 660.101 [Amended]

42. In § 650.101 *U.S. Standard/ Reference Preparations,* in the introductory paragraph by changing "20205" to read "20892."

§ 660.105 [Amended]

43. In § 660.105 *Samples and protocols: official release,* in the introductory text of paragraph (a) by changing "20205" to read "20892."

PART 680—ADDITIONAL STANDARDS FOR MISCELLANEOUS PRODUCTS

44. The authority citation for 21 CFR Part 680 is revised to read as follows:

Authority: Secs. 215, 351, 58 Stat. 690 as amended, 702 as amended (42 U.S.C. 216, 262); 21 CFR 5.10.

§ 680.4 [Amended]

45. In § 680.4 *Short ragweed pollen extracts,* in the introductory text of paragraph (c)(1) by removing the phrase "Building 29A" and by changing "20205" to read "20892."

§ 680.21 [Amended]

46. In § 680.21 *Reference preparations* by changing "20205" to read "20892."

§ 680.26 [Amended]

47. In § 680.26 *Samples; protocols; official release* by removing the phrase "Building 29A" and by changing "20205" to read "20892."

Dated: April 17, 1986.

John M. Taylor,

Acting Associate Commissioner for Regulatory Affairs.

[FR Doc. 86-9119 Filed 4-24-86; 8:45 am]

BILLING CODE 4160-01-M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Secretary

24 CFR Parts 200, 812, 881, 882, and 912

[Docket No. R-85-974; FR-1588]

Restriction on Use of Assisted Housing

Correction

In FR Doc. 86-7050 beginning on page 11198 in the issue of Tuesday, April 1, 1986, make the following corrections:

§ 200.180 [Corrected]

1. On page 11214, third column, in § 200.180(a), seventh line, "1985" should read "1965".

§ 200.182 [Corrected]

2. On page 11215, third column, in § 200.182(a)(5)(i)(A)(*1*), second line, insert "(i)" between "(5)" and "(B)". In § 200.182(a)(5)(i)(A)(*2*), last line, "§ 200.182" should read "§ 200.183".

§ 812.5 [Corrected]

3. On page 11220, third column, in § 812.5, paragraph "(4)(1)" should read "(4)(i)". In § 812.5(a)(4)(i)(A), second line, "PHA.g" should read "PHA.".

4. On page 11221, third column, seventh line, "250-0204" should read "2502-0204".

§ 812.7 [Corrected]

5. On page 11222, first column, in § 812.7(a)(1)(ii)(B), eighth line, "follow" should read "allow".

§ 881.504 [Corrected]

6. On page 11225, first column, in § 881.504(e), eighth line, "than" should read "then".

§ 882.209 [Corrected]

7. On page 11226, first column, in § 882.209(a)(7), thirteenth line, "states" should read "stated".

§ 912.7 [Corrected]

8. On page 11230, third column, in § 912.7(a)(2)(ii), second line, "(d)(2)(i)" should read "(a)(2)(i)".

BILLING CODE 1505-01-M

DEPARTMENT OF JUSTICE

28 CFR Part 0

[Order No. 1131-86]

Organization of the Department of Justice

AGENCY: Department of Justice.

ACTION: Final rule.

SUMMARY: This rule will amend 28 CFR 0.111 by striking the existing language in paragraph (i) and adding a new paragraph to reflect a delegation of authority to the Director of the United States Marshals Service. On March 6, 1984 and May 24, 1985, the Director was delegated the authority to maintain, safekeep, and dispose of assets forfeited to the United States, and to administer the Department of Justice Asset Forfeiture Fund.

EFFECTIVE DATE: April 10, 1986.

FOR FURTHER INFORMATION CONTACT: Gerald M. Auerbach, General Counsel, United States Marshals Service, McLean, Virginia; telephone No. (703) 285-1004, which is not a toll-free number.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated certain authority over asset forfeiture matters to the Director of the United States Marshals Service. This rule will amend 28 CFR 0.111 to add new language to paragraph (i) reflecting this delegation in order to alert the public to the present organizational structure of the Department.

This regulation is not a major rule within the meaning of Executive Order 12291, 3 CFR 127 (1982 Comp.) because it imposes no new requirements. It does not have an impact on small businesses and, therefore, is not subject to the Regulatory Flexibility Act, 5 U.S.C. 601-612. Compliance with 5 U.S.C. 553 as to notice of proposed rule making and delayed effective date is not necessary because this rule relates to agency organization and management.

List of Subjects in 28 CFR Part 0

Organization and functions (Government agencies), Assets, Forfeiture.

By virtue of the authority vested in me by 28 U.S.C. 509, 510, 524, 569, and 5 U.S.C. 301, Subpart T of Part 0 of Title 28 of the Code of Federal Regulations is amended as follows:

1. The authority citation for Subpart T continues to read as follows:

Authority: 28 U.S.C. 509, 510, 524, 569; 5 U.S.C. 301.

2. In Section 0.111, paragraph (i) is revised to read as follows:

§ 0.111 General functions.

* * * * *

(i) Maintenance of custody, management control, and disposal of property and money seized or forfeited pursuant to any law enforced or administered by the Department of Justice, when the property is seized by the United States Marshals Service or delivered to the United States Marshals Service in accordance with regulations; and administer the Department of Justice Asset Forfeiture Fund.

* * * * *

Dated: April 10, 1986.

Edwin Meese III,

Attorney General.

[FR Doc. 86-9161 Filed 4-24-86; 8:45 am]

BILLING CODE 4410-01-M

NATIONAL LABOR RELATIONS BOARD

29 CFR Part 102

Procedural Rules; Advisory Opinion Requests by State Agencies and Courts

AGENCY: National Labor Relations Board.

ACTION: Final rule.

SUMMARY: In response to requests that the Board facilitate the procedure for issuing an advisory opinion to a court or state agency on assertion of jurisdiction over an employing enterprise, the Board is amending §§ 102.98 and 102.99 to allow a court or state agency to request an advisory opinion from the Board as to whether it would assert jurisdiction over that enterprise.

EFFECTIVE DATE: June 1, 1986.

FOR FURTHER INFORMATION CONTACT: John C. Truesdale, Executive Secretary, 1717 Pennsylvania Avenue, NW., Room 701, Washington, DC 20570, Telephone: (202) 254-9430.

SUPPLEMENTARY INFORMATION: Pursuant to its authority under section 6 of the National Labor Relations Act, as amended (29 U.S.C. 156), the National Labor Relations Board is amending its rules that provide for the Board's issuance of advisory opinions on the issue of whether an employer is within the Board's jurisdiction on the basis of its jurisdictional standards. The Association of Labor Relations Agencies (ALRA) petitioned the Board to consider the amendment of §§ 102.98 and 102.103 to enable state labor relations agencies to obtain administrative advice from the Board on whether the Board would assert jurisdiction over a particular employing enterprise. In determining an appropriate procedure, the Board was cognizant of the ALRA's interest in having a readily available, if less formalized, decisional response from the Board than the present advisory opinion procedure provides.

Rather than adopting a separate approach for responding to requests for advisory opinions by state agencies, the Board is amending its rules to allow for an expanded use of the advisory opinion procedure by state agencies and courts. The amendments to §§ 102.98 and 102.99 enlarge the present provisions that apply to requests for advisory opinions by state agencies and courts only when there is a question of whether the Board would assert jurisdiction under its current standards. The amended sections provide for advisory opinions on the broader issue of whether the Board would assert jurisdiction over an employing enterprise, thereby including jurisdiction under the National Labor Relations Act as well as the Board's current standards. The amended procedure utilizes an established procedure culminating in an opinion that would be published in a Board volume. This procedure will provide access to the Board by state agencies and courts on a greater range of jurisdictional issues. Access to the Board by the parties to the state proceeding where the state agency or court does not seek Board assistance is not deemed appropriate.

The remaining provisions pertaining to the advisory opinion process, §§ 102.100 to 102.104, are unchanged.

List of Subjects in 29 CFR Part 102

Administrative practice and procedure, labor management relations.

Accordingly, 29 CFR Part 102 is amended to read as follows:

PART 102—RULES AND REGULATIONS, SERIES 8, AS AMENDED

1. The authority citation for 29 CFR Part 102 is revised to read as follows:

Authority: Section 6, National Labor Relations Act, as amended (29 U.S.C. 151, 156).